OncoMatch/Clinical Trials/NCT07831369
VISTA: Valproic Acid, Irinotecan, and Simvastatin for Recurrent Glioma
Is NCT07831369 recruiting? Yes, currently enrolling (Oct 2026). This Phase 2 trial studies multiple treatments including Valproic Acid (VPA) and Irinotecan for glioblastoma.
Treatment: Valproic Acid (VPA) · Irinotecan · Simvastatin — The goal of this clinical trial is to see if the combination of valproic acid, irinotecan, and simvastatin causes these tumors to stabilize or shrink, which is a sign that these combinations are effective against tumors in patients with recurrent glioblastoma and adults with recurrent IDH-mutated gliomas
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Glioblastoma
Biomarker criteria
Required: IDH1 mutation
IDH-mutated glioma by WHO 2021 classification
Required: IDH2 mutation
IDH-mutated glioma by WHO 2021 classification
Demographics
Prior therapy
Must have received: temozolomide and/or radiation therapy (temozolomide) — glioblastoma
For glioblastoma, at least one prior treatment, which needs to include temozolomide and/or radiation
Must have received: radiation therapy — IDH-mutated glioma
For IDH-mutated glioma, prior treatment with both radiation and alkylating chemotherapy
Must have received: alkylating agent — IDH-mutated glioma
For IDH-mutated glioma, prior treatment with both radiation and alkylating chemotherapy
Cannot have received: irinotecan (irinotecan)
Prior treatment with irinotecan
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Inova Schar Cancer · Fairfax, Virginia
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07831369 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior irinotecan disqualifies patients from enrollment.
Does this trial require IDH1?
Yes, IDH1 mutation is a required biomarker for enrollment.
Does this trial require IDH2?
Yes, IDH2 mutation is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 98 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages